(PDF) Editorial: First Among Equals-Not for Either

Editorial: First Among Equals-Not for Either Infliximab or Adalimumab in Crohn's Disease-Yet

Alimentary Pharmacology and Therapeutics - United Kingdom

doi 10.1111/apt.14549

Full Text

Abstract

Available in full text

Categories

Gastroenterology

Date

March 25, 2018

Authors

G. L. Radford-Smith

Publisher

Wiley

Related search

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

New England Journal of Medicine

English

Infliximab and Adalimumab Drug Levels in Crohn's Disease: Contrasting Associations With Disease Activity and Influencing Factors

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Efficacy of Adalimumab in Patients With Crohn's Disease and Failure to Infliximab Therapy: A Clinical Series

Revista Espanola de Enfermedades Digestivas

Gastroenterology

English

Clinical Efficacy of Adalimumab Versus Infliximab and the Factors Associated With Recurrence or Aggravation During Treatment of Anal Fistulas in Crohn's Disease

Intestinal Research

Gastroenterology

English

Editorial: Infliximab Trough Cut-Off for Perianal Crohn's Disease - Another Piece of the Therapeutic Drug Monitoring-Guided Infliximab Dosing Puzzle

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

English

Editorial: Not Yet Time for Universal Susceptibility-Guided First-Line Helicobacter Pylori Treatment

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis

Alimentary Pharmacology and Therapeutics

Gastroenterology

English

Löfgren Syndrome Developing During Infliximab Therapy for Crohn's Disease: A Case Report

Canadian Journal of General Internal Medicine

English